Handelsavisen
prelaunch
Companies ›Healthcare ›4123.TWO
41
4123.TWO — TPEx Pharmaceuticals

Center Laboratories Inc

$37,80
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
1,86 %
Op margin
-23,9 %
ROE
35,2 %
Net margin
614,9 %
Debt / equity
0,18
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Center Laboratories Inc is a pharmaceutical company that develops, produces, and distributes prescription drugs, primarily in the healthcare sector.

Business. Center Laboratories Inc (4123.TWO) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Japan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
35,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4123.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4123.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Center Laboratories Inc (4123.TWO) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Japan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Center Laboratories Inc exhibits a strong capital structure with a debt-to-equity ratio of 0.18, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.45, suggesting potential short-term liquidity constraints. Despite holding free cash flow of 8.74 billion TWD, the company's cash and equivalents are limited to 15.57 million TWD, which is significantly lower than its long-term debt of 4.7 billion TWD.

    Profitability metrics show a return on equity (ROE) of 35.2% and a return on assets (ROA) of 26.92%, both of which are strong indicators of efficient capital utilization and asset management. The company's net income of 9.32 billion TWD contrasts sharply with its operating loss of 361.62 million TWD, suggesting non-operating gains or one-time events significantly contributed to profitability.

    Geographic and segment exposure data is not available in the provided dataset, but the company's revenue concentration is inferred to be primarily within the pharmaceuticals segment. The company's capital expenditures of -208.21 million TWD indicate a reduction in investment in physical assets, which may reflect a strategic shift or cost-cutting measures.

    Looking ahead, the company's revenue growth trajectory is uncertain, as no specific outlook data is provided in the dataset. However, the company's free cash flow generation of 8.74 billion TWD suggests a capacity to fund operations and potentially invest in growth opportunities. The risk assessment indicates a medium liquidity risk and a low dilution risk, with the key flag being negative net cash after subtracting total debt.

    Recent events, including analyst estimates, show a last actual EPS of 9.28 TWD and a last actual revenue of 21.65 billion TWD, which may influence investor sentiment and valuation expectations.

    Key takeaways
    • Center Laboratories Inc has a strong ROE of 35.2% and ROA of 26.92%, indicating efficient capital and asset utilization.
    • The company's liquidity position is constrained, with a current ratio of 0.45 and limited cash and equivalents.
    • Despite a significant net income, the company reported an operating loss, suggesting non-operating gains contributed to profitability.
    • The company's debt-to-equity ratio of 0.18 indicates a conservative capital structure with low debt reliance.
    • Free cash flow generation of 8.74 billion TWD provides flexibility for operations and potential growth investments.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $37,80
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $26.49B
    Net cashⓘ
    -$4.69B
    Current ratioⓘ
    0.5
    Debt / equityⓘ
    0.2
    ROAⓘ
    26.9%
    ROEⓘ
    35.2%
    Cash conversionⓘ
    0.0%
    CapEx / revenueⓘ
    -13.7%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-23,8 %Bottom quartile
    Net Margin614,9 %Best in class
    ROE35,2 %Best in class
    Capex / Rev-13,7 %Below median
    D/E0,18Below median
    Cash Conv0,00Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Center Laboratories Inc Market data — financials · 2026-05-26
    • Center Laboratories Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4123.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage